• slide_obamacare_greaterthan

  • slide_prepvideos

  • Slideshow_hivhealthreform

  • Slideshow_prep

  • Slideshow_coinfection

IAS2015: Maintenance HIV regimen of rilpivirine and boosted darunavir as effective as three-drug treatment in early results

post_2015IAS_sm

A presentation at the 2015 International AIDS Society conference in Vancouver reported 24-week results comparing a maintenance regimen of rilpivirine (Edurant) + boosted darunavir (Prezista/ritonavir) to a three-drug regimen of a boosted protease inhibitor and two NRTIs. This could offer some people a new treatment option should…Read More

IAS2015: START study confirms the benefits of starting HIV treatment at any CD4 count

post_2015IAS_sm

by Alan McCord, Director of Education A presentation at the 2015 International AIDS Society conference in Vancouver reported additional results from the START (Strategic Timing of Antiretroviral Treatment) Study that showed significant benefits to starting HIV treatment earlier rather than waiting until later to start: a 57%…Read More

Positively Aware publishes special summer issue on PrEP

PA_PrEP_0715_sm

Positively Aware has published a special issue devoted solely to PrEP (Pre-Exposure Prophylaxis). Awareness around PrEP is rapidly increasing around the US, and this issue highlights the personal stories of people on PrEP, the clinical research, ways to access PrEP, and dealing with a difficult provider relationship. Project Inform’s…Read More

IAS2015: Daily dosing and text message reminders associated with PrEP adherence in gay men

post_2015IAS_sm

by David Evans, Director of Research Advocacy Two studies presented at the 8th International AIDS Society conference in Vancouver, Canada offered a look at factors associated with adherence to PrEP in men who have sex with men (MSM). In an oral presentation, researchers with the HPTN…Read More

IAS2015: New NNRTI doravirine as effective as efavirenz in people new to HIV treatment in early study

post_2015IAS_sm

by Alan McCord, Director of Education An oral presentation at the 2015 International AIDS Conference in Vancouver this week reported 24-week results comparing the new NNRTI doravirine to efavirenz. Both drugs were combined with emtricitabine/tenofovir (Truvada). The new NNRTI doravirine may offer benefits compared with the…Read More

IAS2015: New maturation inhibitor BMS 176 shows potent control of HIV in small study

post_2015IAS_sm

by Alan McCord, Director of Education An oral presentation at the 2015 International AIDS Conference in Vancouver this week reported promising results from an early 28-day, Phase IIa study of a new maturation inhibitor called BMS-955176. Maturation inhibitors act at the last step of the HIV…Read More

IAS2015: New PrEP & women studies: High adherence and effectiveness, but caution for providers

post_2015IAS_sm

by David Evans, Director of Research Advocacy Two studies presented at the 8th International AIDS Society in Vancouver Canada (July 19 to 23) offer critical insights about PrEP and cisgender heterosexual women. One found very high rates of adherence and no infections among women taking daily…Read More